Angiotensin II type 1 receptor gene polymorphism as a genetic marker for developing hypertension and metabolic syndrome
Document Actions
A total of 420 white hypertensive subjects never treated for hypertension and followed up for 7.3 years in the Hypertension And Ambulatory Recording Venetia Study (HARVEST) were included in the analysis in order to investigate the effect of polymorphism A1166C for angiotensin II type 1 receptor (AGTR1) and -1332G/A for AGTR2 on the incidence of sustained hypertension and metabolic syndrome in a cohort of young patients screened for stage 1 hypertension. The outcome measures included incident physician-diagnosed hypertension, increase in ambulatory blood pressure, and new-onset metabolic syndrome. Whereas no association was found between AGTR2 polymorphism and any outcome measure, 37.2% of subjects with AA genotype for AGTR1, 47.5% of those with AC genotype, and 66.7% of those with CC genotype developed hypertension during follow-up. Furthermore, the increase in ambulatory systolic and diastolic blood pressure was higher in patients with CC genotype than in the rest of the group. Cox analysis revealed that subjects with CC genotype had an increased risk of developing hypertension and metabolic syndrome compared to AA subjects. The AGTR1 A1166C polymorphism may be considered as a genetic marker predisposing to increased blood pressure and development of metabolic syndrome over time in subjects screened for stage 1 hypertension.
Abstract
